Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate the effect of daily oral administration of
80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in
patients with PBC and inadequate response or intolerance to Ursodeoxycholic Acid (UCDA)